Learn / Epidemiology / Screening and diagnostic tests
Principles of screening and its hidden biases
14 minute read · 6-question quiz
What you will learn
State the Wilson and Jungner criteria and apply them to a proposed programme
Explain lead-time, length and overdiagnosis biases
Calculate the yield and false-positive burden of a screening programme
Screening is the application of a test to people without symptoms to identify those at increased risk of a disease, so that early treatment improves their outcome. It differs from diagnosis, which investigates people with symptoms. Screening harms healthy people if done badly: false alarms, anxiety, unnecessary treatment.
The Wilson and Jungner criteria (WHO, 1968, summarised)
The condition
An important health problem, with a recognisable latent or early symptomatic stage and a known natural history.
The treatment
An accepted, effective treatment; earlier treatment must do better than treatment at the usual time. Facilities for diagnosis and treatment are available.
The test
Suitable, simple, safe and acceptable; adequate sensitivity and specificity; an agreed policy on whom to treat.
The programme
Cost balanced against benefit; case-finding is a continuing process, not 'once and for all'.
Why screening studies are hard to interpret: three biases
Lead-time bias. Screening finds the disease earlier but the person may die at the same time. Survival measured from diagnosis then looks longer without any real benefit. Suppose a cancer is found by screening at age 60 and the patient dies at 66 (survival 6 years). Without screening, the same cancer is diagnosed by symptoms at 63 and the patient still dies at 66 (survival 3 years). Treatment gained nothing; the clock simply started earlier. The antidote: compare mortality in the screened and unscreened populations, not survival times.
Length bias. Screening, performed at intervals, is more likely to catch slow-growing, less aggressive disease (it spends longer in the detectable phase) than fast-growing disease that appears between screens. Screen-detected cases therefore look to have a better prognosis.
Overdiagnosis. Screening can detect 'disease' that would never have caused symptoms or death in the person's lifetime (some prostate and thyroid cancers). Treating it adds harm and no benefit. Overdiagnosis is invisible in an individual and only revealed by population comparisons.
Summary
Screening tests asymptomatic people to find disease earlier; harms to healthy people must be weighed.
Wilson and Jungner criteria cover the condition, treatment, test and programme.
Even a good test has a low PPV when prevalence is low.
Lead-time, length and overdiagnosis biases make survival after diagnosis unreliable.
Mortality in a randomised comparison is the valid outcome of a screening programme.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.